About Cellfield

Cellfield Pty Ltd is an Australian company, based in Southport Queensland, whose registered address is in Sydney. It was incorporated in March 2001 to deliver the innovative new Cellfield treatment for severe reading disorders.

The Chairman of Cellfield is Australian Robert Sauer, who is also a lawyer in a Sydney law firm. He has had a long career in innovation, serving on the boards of several innovation based companies and serving on the Industrial Research and Development Board of the Australian Government.

The Cellfield CEO is Dimitri Caplygin, who is also the inventor. Dimitri came to Australia in 1950 as a refugee from Russia. Despite a flair for music and art, both of which he studied for 10 years, he chose another path and gained a Bachelor's degree in Science and Engineering from UNSW. An analytical mind and a creative flair earned him the responsibility for Research & Development at an early age, which became part of his responsibilities for more than twenty years. During this time, he won two national prizes for Australian design. He set up and managed a Research Facility in Singapore for eleven years, which amongst many things also provided him with a deeper understanding of computer science that proved essential for the Cellfield treatment.

Dimitri returned to Australia in 1995. As he had done several times before in his working life, Dimitri sought a new direction that had connections with his past. A chance encounter with severe reading disorders provided that connection in an emotive way, which led to that familiar inventive 'flash'. Dimitri was moved by the widespread suffering of dyslexics and was bewildered by the positions of exclusivity taken by many scientists as to the causes of dyslexia. With the fresh eyes of an outsider, Dimitri thought their positions were largely not contradictory, but part of a continuum of causes that could be tied together through computer science.

Dimitri lodged provision patent applications in 1999 for the Cellfield treatment. It took a further two years to find the seed capital required to conduct a pilot trial, which was completed in 2001. The first Clinic in Queensland was opened early in 2002.